Background: Plaintiffs allege that Talis and its senior officers and directors violated Sections 11 and 15 of the Securities Act of 1933 by misrepresenting the effectiveness, regulatory status, and ability to manufacture the company’s “Talis One” COVID-19 test in the offering documents for Talis’s initial public offering.

BFA’s Role: BFA was appointed Co-Lead Counsel for the putative class on June 3, 2022.

Status: BFA filed a second amended class action complaint on January 13, 2023.  On April 28, 2023, the Court denied defendants’ motion to dismiss.  Lead Plaintiff Martin Dugan’s motion for class certification was granted on February 9, 2024. On October 1, 2024, BFA moved for preliminary approval of a $32.5 million class settlement.